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Abstract Colorectal cancer is not just one type of cancer.
Differences in outcome and reaction to treatment can at least
be partly explained by different histological and molecular
subtypes. Recognition of these differences may influence
treatment decisions. However, there is huge variation in the
amount of information that is available. Several tumour types
such as mucinous carcinoma, signet ring cell carcinoma, neu-
roendocrine carcinoma and adenosquamous carcinoma have
such a distinct phenotype that they are readily recognised.
However, due to the rarity of signet ring cell carcinoma and
adenosquamous carcinoma, limited data are available. More
recently defined subtypes, like medullary carcinoma, serrated
adenocarcinoma and micropapillary carcinoma, are not ade-
quately diagnosed, which limits research possibilities using
large-scale data from registries. In the current review, we sys-
tematically describe the histologic subtypes with the clinical
and molecular background. We evaluate their prognosis com-
pared to adenocarcinoma not otherwise specified and specu-
late about the clinical relevance.
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Introduction
Differences in oncological outcome of cancer have been long
recognised, and with the apparently limitless possibilities of
next-generation sequencing, it has been shown that at least
part of these differences can be ascribed to the molecular
background. However, the influence of tumour microenviron-
ment should not be ignored and might very well be responsi-
ble for the limited responsiveness to therapy in a percentage of
tumours [1]. Both molecular background and tumour-
microenvironment interactions are closely associated with tu-
mour type. This phenotypic determination of the character of
tumour cells has been shown to be very relevant for prognosis.
In colorectal cancer, mucinous carcinoma, the most frequent
of the well-recognised subtypes, has a very limited response to
systemic therapy in the metastatic setting, probably due to the
distinct pattern along which the tumour disseminates [2]. Sol-
itary liver metastases are uncommon in mucinous carcinomas,
whereas peritoneal spread is more common.
Several subtypes have been recognised for a very long
time, due to the clear differences in their phenotypes com-
pared to the common adenocarcinoma (AC). Mucinous carci-
noma (MC, Fig. 1a) is the most frequent phenotype in this
group and therefore relatively well-studied. The other sub-
types like signet ring cell carcinoma (SRCC, Fig. 1b), neuro-
endocrine carcinoma (NEC, Fig. 1c) and adenosquamous car-
cinoma (ASC, Fig. 1d) are very rare, and therefore, limited
information can be gathered about their response to therapy.
More recently, three additional subtypes have been defined, at
least partly based onmolecular and genetic studies. Medullary
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carcinoma (MeC, Fig. 1e) has a very strong correlation with
microsatellite instability and Lynch syndrome, while serrated
carcinoma (SeC, Fig. 1f) is strongly linked to the serrated
pathway among which colorectal cancer can develop. Finally,
in analogy with breast carcinoma and other tumour types, the
micropapillary subtype has been recognised (MiC, Fig. 1g). In
the general population, there is underreporting of these sub-
types, because of insufficient recognition in daily practise.
Evidence for aberrant clinical behaviour is only derived from
single-centre studies and therefore needs validation in
larger series.
In this review, we describe the different subtypes with the
molecular background (if known) in correlation with clinical
relevant issues and outcome data.
Mucinous Carcinoma
In the spectrum of colorectal cancer (CRC), MC is the second
largest histological subtype next to AC (10–15 % of CRCs)
[1]. A tumour is designated as MC when more than 50 % of
the tumour volume consists of extracellular mucus [3]. In the
pools of mucus, malignant epithelium can be found in clumps
of cells or as single cells [4]. The distinct histological presen-
tation of MC has led to the hypothesis that these tumours may
develop along a distinct oncogenic pathway, but exact mech-
anisms have not been elucidated to date. MCs have a tendency
to be located in the right hemicolon (54–60%), they present at
a more advanced stage of disease, and high frequencies ofMC
are observed in Lynch syndrome patients (22–40 %) [1, 5–7].
The latter also explains the higher rate of microsatellite insta-
bility (MSI) that is seen in MC [7]. However, when MCs do
develop according to the chromosomal instability pathway,
they present with a markedly lower rate of chromosomal in-
stability compared with ACs [8]. Other common molecular
aberrations in MC are the higher rates of KRAS, BRAF and
PI3K mutations, when compared with AC [7]. Constitutive
activation of the RAS/RAF/MAPK and PI3K/AKT signalling
pathways influences cell growth, survival, proliferation and
cell motility, thus influencing tumour behaviour.
Since MC is diagnosed approximately once in every eight
CRC patients, the prognostic value of this subtype has been
studied extensively, but discussion remains. MC in general
has long been considered an unfavourable prognostic indica-
tor, but this has been disputed in various studies recently. In
this perspective, the importance of the location of the primary
tumour has been highlighted, since treatment strategies and
prognosis vary for colon and rectal cancer patients.
For colonic MC, large population-based studies have dem-
onstrated that there is no difference in overall survival after
correction for stage at presentation [1, 5, 9]. Moreover, in a
recent retrospective cohort study of 435 non-metastatic pa-
tients who were diagnosed with CRC between 2000 and
2010, it was demonstrated that MC was associated with an
improved outcome (HR 0.75; 95 % CI 0.46–1.21). This
favourable outcome has not been reported for rectal MC to
date, and the controversy regarding prognosis in rectal MC
patients has been ongoing over the past few decades. Rectal
MCs tend to respond poorly to neoadjuvant therapies such as
chemoradiotherapy, and high rates of incomplete resections
have been reported [10, 11, 12••]. However, when adequate
circumferential resection margins can be obtained during sur-
gery, there is no difference in local recurrence rate and overall
survival between rectal MC and AC [13]. Multidisciplinary
assessment of rectal cancer patients including accurate imag-
ing, optimal preoperative therapy and high-quality total
mesorectal excision surgery has demonstrated to improve out-
come for rectal MC [13] (Table 1).
As mentioned afore, MCs present at a higher stage of dis-
ease compared with ACs. Between 19 and 29 % of MC
Fig. 1 Different histological
subtypes of colorectal cancer. a
Mucinous carcinoma (MC), b
signet ring cell carcinoma
(SRCC), c neuroendocrine
carcinoma (NEC), d
adenosquamous carcinoma
(ASC), e medullary carcinoma
(MeC), f serrated carcinoma
(SeC) and g micropapillary
carcinoma (MiC)
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patients have metastatic disease upon their first presentation,
andMCs are more likely to develop metastases during follow-
up [1, 2, 5]. Although mechanisms are unclear, it has been
demonstrated that MC has a distinct metastatic pattern of
spread than AC. MC patients more frequently have metastatic
disease in more than one organ. Compared with AC, hepatic
metastases are less common in MC, and especially peritoneal
metastases are frequently seen [2].
The deviant metastatic pattern of MCs is considered one of
the possible explanations for the poor outcome after palliative
chemotherapy as observed in various studies [12••, 14–17].
Median overall survival rates for MC patients from these stud-
ies are approximately 12 months, suggesting a reduced effica-
cy of chemotherapy for advanced-stage MC [12••]. In the
adjuvant setting, no difference in outcome following
chemotherapy has been observed when compared with
AC [9, 12••, 18].
Signet Ring Cell Carcinoma
Signet ring cell carcinoma (SRCC) is a rare subtype (1 % of
CRCs) and is defined by the presence of the typical signet ring
cells that comprise at least half of the tumour volume [1, 3].
Signet ring cells get their typical appearance as a result of a
large mucus vacuole that displaces the nucleus to the edge of
the cell. Compared with AC patients, SRCC patients are gen-
erally younger. Over 25 % of SRCC patients is under the age
of 60 [1]. As for MC, SRCC is commonly found in the prox-
imal (right) hemicolon inmore than half of the patients [1, 19].
This corroborates very well with the high rate of MSI that is
seen in SRCC tumours (24–40%) [20, 21]. Especially SRCCs
that also present with extensive mucus surrounding the tu-
mour are likely MSI [20]. SRCCs are frequently of the CpG
island methylator phenotype (48 %), and BRAFmutations are
found in 30–33 % of SRCCs [20, 21]. KRAS is mutated in
53 % of SRCCs [21]. SRCCs are notorious for their rapid
progression to an advanced stage of disease and are more
likely to present with locally advanced and lymph node-
positive tumours, with over three quarter of tumours being
stage III or IV at the time of diagnosis [1, 5]. Perineural
growth and lymphatic and vascular invasion are fre-
quently present [20].
Approximately one third of SRCC patients already has
metastatic disease upon the first presentation, and SRCC pa-
tients are more likely to develop metastases during follow-up
[1, 2, 5]. SRCC has a distinct metastatic pattern, in which
metastases develop at multiple sites (71 %). Liver metastases
only account for 32 % of metastases in SRCC patients, and
metastases to the peritoneum are seen in 51 %, compared with
73 and 20 %, respectively, in AC patients [2]. Especially peri-
toneal metastases in CRC are clinically challenging, but the
introduction of cytoreductive surgery followed by hyperther-
mic intraperitoneal chemotherapy (HIPEC) has shown prom-
ising results and has improved prognosis for this patient group
[22]. Unfortunately, for SRCC patients, a high rate of
Table 1 Overview of studies that analysed overall survival of colorectal SRCC patients compared with AC patients using multivariable or univariable
analysis
Hazard ratios as reported in studies were used for analysis. If no hazard ratio was reported, it was calculated from the published data as described by
Parmar et al. [69]
aMultivariable analysis
b Univariable analysis
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recurrence after HIPEC has been shown, resulting in a meagre
median survival reaching only slightly over 1 year [23•, 24].
This had led to the recommendation to refrain from aggressive
therapeutic approaches for peritoneal SRCC metastases in the
presence of other poor prognostic factors [23•].
Prognosis for SRCC patients is not only poor for advanced-
stage disease. SRCCs have stage-independent poorer out-
comes when compared with AC [5, 25–33]. A study from
2015 showed that poorer outcomes were seen in both colon
and rectal cancer patients separately, with 5-year relative sur-
vival rates of 30.8 and 19.5 %, respectively [1].
Despite the poor reported outcome, the clinical subset of
SRCC patients is too small to being addressed in clinical stud-
ies, rendering insight into response to therapies limited. Al-
though a poor outcome for metastatic patients following
cytoreductive surgery and HIPEC has been described, benefit
of adjuvant chemotherapy seems comparable with AC [1].
Additional analyses are highly needed and may give more
direction in therapeutic strategies.
Neuroendocrine Carcinoma
Neuroendocrine carcinomas form the end of a spectrumwhich
ranges from adenocarcinomas with neuroendocrine differen-
tiation via MANEC (mixed adenoneuroendocrine carcinoma)
to NEC. With the introduction of immunochemistry and anti-
bodies that were specific for neuroendocrine differentiation,
large series of adenocarcinomas have been analysed. For the
current review, we exclude the carcinoids, but in many studies,
these are analysed in combination with NEC.
Differentiated neuroendocrine cells have been detect-
ed either scattered through the tumour or in distinct
nests in approximately 20 % of adenocarcinomas [34].
When applying a definition of less than 30 % of neu-
roendocrine differentiation in tumour, a recent meta-
analysis [34] including 1587 patients from 11 studies
shows that neuroendocrine differentiation in adenocarci-
nomas is associated with a decreased 5-year survival
rate (pooled OR 0.60, 95 % CI 0.37–0.97). This is in
line with the recent publication of Shafqat et al. [35•].
MANEC was first defined in the 2010 edition of the WHO
Blue Book [3] and describes tumours with both adenocarci-
noma and neuroendocrine carcinoma components that each
has a proportion of at least 30 %. Current literature is mainly
limited to case reports. One study [36] compared 12 patients
with MANECwith 27 patients with NEC and did not find any
differences in survival.
There has been an increase in the incidence of colorectal
neuroendocrine tumours over recent years [35•]; however,
these tumours still account for a very small contingent of
colorectal carcinomas, less than 1 %. From studies that com-
pared the small adenocarcinoma components of these tumours
with the neuroendocrine components [37–39], we know that
both components have a clonal relationship, which can be
traced back to the adenomatous stage. Mutational status
(KRAS, BRAF, NRAS, PIK3CA, p53) in these tumours is
not different from adenocarcinomas [39].
Compared to high-grade AC [35•], patients with NEC
are younger, more often male. Tumours present as met-
astatic disease, and the primary location is more often
in the rectum. In this large registry-based analysis, the
5-year overall survival of patients with NEC (n=1367)
was very poor, even compared with high-grade AC (n=
72,553), 16.3 versus 50.2 %. Similar data are obtained
in an earlier SEER-derived study, where 455 NECs
identified between 1992 and 2000 with a relative 5-
year survival of 21.4 % were compared to all adenocar-
cinomas (5-year relative survival 62.1 %) [40]. This is
in line with the data obtained from the NORDIC NEC
study [41], where NECs derived from the colon and
rectum demonstrate the worst survival rates of all NECs
of the gastrointestinal tract.
Adenosquamous Carcinoma
Like NEC, ASC is also part of a spectrum, which ranges from
adenoacanthoma (i.e. adenocarcinomas with benign-
appearing squamous metaplasia) through ASC to pure squa-
mous carcinoma. The first and the latter are extremely rare.
Cancer registries estimate the incidence of ASC between 0.06
and 0.09 % [42, 43]. Patient characteristics are not different
from adenocarcinomas, but these tumours tend to present in
advanced stages [42] and are located more often in the prox-
imal and transverse colon, compared to AC. When they are
located in the rectosigmoid area, the prognosis seems slightly
better [43]. In early-stage disease (pT1-3N0), outcomes are
comparable to AC; however, all other tumours have a signif-
icantly worse outcome, which is most pronounced in patients
with synchronous metastases. Five-year overall survival is
23.5–25.4 % compared to 41.6–53.6 % in AC [42, 43]. How-
ever, these data are based on a total number of 244 patients.
Molecular data and information about treatment response are
not available.
Medullary Carcinoma
MeC, previously known as solid-type poorly differentiated
carcinoma and large cell minimally differentiated carcinoma,
is characterised by sheets of malignant cells with vesicular
nuclei, prominent nucleoli and abundant eosinophilic cyto-
plasm, exhibiting prominent infiltration by intraepithelial lym-
phocytes [3]. Single-centre studies estimate its frequency at
approximately 4 % [44–46]. It is assumed that this type is
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underreported in cancer registries (0.08 %) [47], since it might
be difficult to distinguish from poorly differentiated adenocar-
cinoma [48]. This subtype can be difficult to recognise, espe-
cially on preoperative biopsies, because of the undifferentiated
appearance and the aberrant immunohistochemistry. Because
of the lack of staining with cdx2 [49] and cytokeratin 20, it has
been suggested that these tumours lose their intestinal
differentiation. However, other intestinal markers, such
as MUC1, MUC3 and TFF3, can still be demonstrated
in MeC [50].
MeC is more frequent in female patients [45, 51] and
has a very strong correlation with age, with an in-
creased frequency in the elderly [51]. The preferred lo-
cation is the right colon [44, 45]. These tumours are
larger in size [44, 45], and upon diagnosis, it is hard
to detect premalignant mucosa [44]. Compared to poorly
differentiated adenocarcinoma, less nodal positivity and
less extramural vascular invasion (EMVI) are present
[44]. Compared to AC, more frequent lymphovascular
invasion (LVI) is detected (62.9 versus 36.5 %) [45].
This subtype is invariably associated with MSI and a
very high rate of BRAF mutations: 86 versus 69 % in
other MSI tumours and 19 % or less in the general
population [45].
In general, the prognosis is very good, compared to adeno-
carcinoma [44, 52]. The study of Knox et al. [45] failed to
show this favourable prognosis in the univariate analysis, due
to an unexplained high 30-day mortality in this group, but in
the multivariate analysis there is an improved survival (HR
0.54, 95 % CI 0.30–0.96). There are no data about treatment
response.
Serrated Adenocarcinoma
The recognition of the serrated pathway as an important
developmental route towards CRC has led to the prop-
osition of SeC. This subtype is characterised by archi-
tectural similarity to sessile serrated lesions, with glan-
dular serration, that may be accompanied by mucinous
areas. The cells have a low nucleus-to-cytoplasm ratio
[3]. However, all the available literature is from the
same group of invest igators , which l imits the
generalisability of the data. The data concerning SeC
are lacking behind the enormous amount of information
we are gathering about the serrated polyp [53].
Approximately 10 % of all CRCs can be classified as SeC
[54]. One of the remarkable but also confusing features of SeC
is that both a mucinous and a non-mucinous subtype exist.
Actually, up to 45% of all SeC occur in mucinous carcinomas
[55]. In general, these tumours are more often proximally
located [54] and have similar stage distribution when com-
pared to AC. Microsatellite instability rates are not different
from AC [55], but BRAF mutations are very frequent (33.3
versus 0 %) [56]. In addition, KRAS mutations are frequently
observed (45.2 versus 27.1 %) [56]. These mutation rates are
similar to the ones observed in serrated polyps. In the SeC,
there is co-occurrence of KRAS mutations and MSI, which is
absent in AC. When performing unsupervised clustering
of expression data of SeC and AC, over 200 genes are
differentially expressed [57], and almost perfect separa-
tion occurs. Large-scale microarray studies suggest that
a molecularly defined subtype called CSS3 exists that
might be exemplary for this subtype [58]. However, the
proper histological classification of the tumours in this
study has not been performed. A lack of response to
anti-EGFR therapy independent of KRAS status has
been suggested based on in vitro experiments [58].
The (unclassified) adenocarcinomas in this molecular
subgroup also have a decreased prognosis; however, in
the three available series of SeC, no difference in sur-
vival compared to AC has been observed [54, 57, 59].
Micropapillary Carcinoma
This tumour is characterised by small clusters of tumour cells
within stromal spaces mimicking vascular channels [3]. Ini-
tially described in breast cancer, the subtype has been
recognised in other tumour types as well. The micropapillary
component can be recognised in both AC as MC, and most
studies define their tumour as MiC when they have at least a
5 % component.
The incidence of this component varies between 5
and 20 % of all colorectal carcinomas [60–62]. Data
from cancer registries are not available. The age and
gender of the patients are not different from AC, and
location within the colon is also comparable [60–62].
Not all studies agree about the increased T stage which
is sometimes described [60–62], but in all populations,
the percentage of node-positive patients is high, up to
80 %, compared to an average of 40 % in the AC
patients [60–64]. This is in accordance with almost dou-
ble the incidence of LVI [60–62, 64]. EMVI is in-
creased (46.7 versus 19.1 %), as is perineural invasion
(PNI) [60, 63]. The risk of both positive nodes and LVI
increases with an increasing percentage of the
micropapillary component [60–62].
A number of studies have examined the molecular back-
ground of this new subtype. Microsatellite instability is not
different fromAC [61, 64] or possibly somewhat less frequent
[60]. There is no difference in mutational spectrum (p53,
KRAS, BRAF) [60]. The prognosis of this group of patients
is worse [61, 63, 65]. The study of Lee [61] evaluated the
effects of chemotherapy in 34MiC patients, of which 27 were
treated with systemic therapy, and in the survival curves, no
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difference can be observed. However, due to small numbers,
no conclusions can be drawn. The decreased prognosis in
combination with the sometimes observed high-grade cyto-
logic features [60] has led to the suggestion that this
tumour subtype should be graded as poorly differentiat-
ed [66] (Table 2).
Conclusions
There is more than one type of CRCs. Increasing recognition
of different developmental pathways important in both carci-
nogenesis and treatment response has led to a renewed interest
in histological subtypes. While the molecular background of
tumours is extremely important, the interaction with the mi-
croenvironment should not be forgotten. The presence of an
extensive inflammatory infiltrate, as can be observed in MeC,
is strongly associated with a very good prognosis [67•]. In-
deed, we do observe a good outcome in this patient group,
despite advanced T stage and increased presence of LVI. That
there is more than the molecular background of tumours is
also observed in MiC. Mutational status of these tumours
seems comparable to AC; however, prognosis is significantly
decreased, possibly due to the high frequency of LVI and
EMVI, in combination with very high percentages of lymph
node metastases.
Unfortunately, with the exception of MC, we have little
data on response rates to chemotherapy in these subpopula-
tions and hence very limited data about optimal treatment
regimens. Careful histological and molecular analysis of tu-
mours in clinical trials is required to fill this gap [68]. In
addition, pathologists have to provide this information in the
multidisciplinary meetings and explain the possible impact of
these different subtypes properly. The issue of the different
histologies of colorectal cancer should be put on the agenda
of future oncology meetings to raise awareness on the
different response rates, natural history and outcomes of
the individual types.
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